NASDAQ
LIXTW

Lixte Biotechnology Holdings Inc

Prices are adjusted according to historical splits.

Lixte Biotechnology Holdings Inc Stock Price

Vitals

Today's Low:
$0.059
Today's High:
$0.06
Open Price:
$0.06
52W Low:
$0.037
52W High:
$0.28
Prev. Close:
$0.053
Volume:
1200

Company Statistics

Market Cap.:
$39.49 million
Book Value:
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-76.02%
Return on Equity TTM:
-34156.66%

Company Profile

Lixte Biotechnology Holdings Inc had its IPO on 2020-11-25 under the ticker symbol LIXTW.

The company operates in the sector and industry. Lixte Biotechnology Holdings Inc has a staff strength of 1 employees.

Stock update

Shares of Lixte Biotechnology Holdings Inc opened at $0.06 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.06 - $0.06, and closed at $0.06.

This is a +11.32% increase from the previous day's closing price.

A total volume of 1,200 shares were traded at the close of the day’s session.

In the last one week, shares of Lixte Biotechnology Holdings Inc have increased by +59.46%.

Lixte Biotechnology Holdings Inc's Key Ratios

Lixte Biotechnology Holdings Inc has a market cap of $39.49 million, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months Lixte Biotechnology Holdings Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Lixte Biotechnology Holdings Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Lixte Biotechnology Holdings Inc’s operating margin was 0% while its return on assets stood at -76.02% with a return of equity of -34156.66%.

In Q2, Lixte Biotechnology Holdings Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Lixte Biotechnology Holdings Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lixte Biotechnology Holdings Inc’s profitability.

Lixte Biotechnology Holdings Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

Lixte Biotechnology Holdings Inc stock pays annual dividends of $ per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$3.10 million
Total Liabilities
$402614.00
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Lixte Biotechnology Holdings Inc ended 2024 with $3.10 million in total assets and $0 in total liabilities. Its intangible assets were valued at $3.10 million while shareholder equity stood at $2.69 million.

Lixte Biotechnology Holdings Inc ended 2024 with $0 in deferred long-term liabilities, $402614.00 in other current liabilities, 166.00 in common stock, $-46430713.00 in retained earnings and $0 in goodwill. Its cash balance stood at $2.91 million and cash and short-term investments were $2.91 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

Lixte Biotechnology Holdings Inc’s total current assets stands at $3.10 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $366528.00 and inventory worth $0.

In 2024, Lixte Biotechnology Holdings Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Lixte Biotechnology Holdings Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.06
52-Week High
$0.28
52-Week Low
$0.037
Analyst Target Price
$

Lixte Biotechnology Holdings Inc stock is currently trading at $0.06 per share. It touched a 52-week high of $0.28 and a 52-week low of $0.28. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.07 and 200-day moving average was $0.08 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About Lixte Biotechnology Holdings Inc

The stock symbol (also called stock or share ticker) of Lixte Biotechnology Holdings Inc is LIXTW

The IPO of Lixte Biotechnology Holdings Inc took place on 2020-11-25

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures, which might be useful in the treatment of cancers, and vascular and metabolic diseases; and LB-200 series for the treatment of chronic hereditary diseases, such as Gaucher’s disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and study with the National Cancer Institute. The company was founded in 2005 and is based in East Setauket, New York.

Address

248 Route 25A, No. 2, East Setauket, NY, United States, 11733